504 related articles for article (PubMed ID: 25085839)
21. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
22. Correlation between BRAF
Geng J; Wang H; Liu Y; Tai J; Jin Y; Zhang J; He L; Fu L; Qin H; Song Y; Su J; Zhang A; Wen X; Guo Y; Ni X
Sci China Life Sci; 2017 Jul; 60(7):729-738. PubMed ID: 28646474
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
24. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
25. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
[TBL] [Abstract][Full Text] [Related]
26. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
27. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
28. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
29. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
30. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
31. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
32. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
33. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
34. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
35. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
36. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
Meng C; Gao J; Liang J; Liang ZY; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
38. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
39. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]